Can a new pill slow kidney damage in IgA nephropathy?
NCT ID NCT07750665
First seen Aug 06, 2026 · Last updated Aug 07, 2026 · Updated 1 time
Summary
This study is testing whether an experimental drug called FXS6837 can safely reduce protein in the urine and help preserve kidney function in people with IgA nephropathy, a disease that can lead to kidney failure. About 60 patients who previously completed a shorter study of FXS6837 will take the capsule daily for two years. Researchers will monitor side effects and measure changes in urine protein levels to see if the drug continues to work over the long term.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- FXS6837 capsule
- What this could lead to
- If successful, FXS6837 could offer a long-term treatment option to slow kidney damage and delay the need for dialysis or transplant in IgA nephropathy.
- What could go wrong
- This is a phase 2 study with a small number of participants, so results may not apply broadly. The drug may cause side effects, and long-term safety and effectiveness are not yet established.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PRIMARY IGA NEPHROPATHY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Peking University First Hospital
Beijing, Beijing Municipality, 100034, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a gut metabolite shield the kidneys in IgA nephropathy?
- Can a new pill protect kidneys from IgA nephropathy?
- New pill aims to tame kidney disease in Long-Term trial
- New pill aims to slow kidney disease in IgA nephropathy patients
- New drug aims to protect kidneys in IgA nephropathy patients
- New drug aims to reduce kidney damage in IgAN patients